Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
about
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Effect of Momordica charantia protein on proliferation, apoptosis and the AKT signal transduction pathway in the human endometrial carcinoma Ishikawa H cell line in vitro.Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma.Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.Investigational drugs for head and neck cancer.Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinomaResponse-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Upregulation of pAKT(Ser473) expression in progression of HPV-positive oropharyngeal squamous cell carcinoma.ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Leveraging Genomics for Head and Neck Cancer Treatment.Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway.mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer
P2860
Q26765429-E6CB0B83-1123-4A77-81B2-1839F2130BC4Q33684917-23EF044F-A498-41FC-AA34-89A6FFCF55D4Q37670693-BAC914CA-C4F2-4F10-AFC8-C19165B117AFQ37690668-C3F29225-D992-48C3-BFBD-A3CA537F0343Q38752793-FF10C6F8-6E7A-45CA-B642-B1F19033F4A5Q38800788-904BD5A9-D8C6-4517-927D-6118CD6C20F9Q38817479-D0D0ACD9-CC6C-4C1C-822F-EF7FC20D0E29Q38818008-C9C1F1B1-067D-4068-8133-89F72C24C5D9Q38838071-A886B2EA-2774-43EE-8353-074CBDD82FC8Q39097109-CB5B5F02-E06F-4F9C-BC25-9E271A7E2DEBQ44952098-BCF9D79F-35C9-4D71-9E75-5BEC88C4F7C1Q45790068-14613475-C634-45F2-8618-89E3AF4888D0Q47748258-6A50EBE7-FAD1-4C87-8F21-015109F22304Q48651245-A87EA25F-71BA-4592-8B74-E63C50AADFA1Q49888021-DE0CFF63-D81C-4B59-A0F0-9CCBC612E6E1Q50116331-43508458-6F5C-4DBD-A58A-FA19BE5427ADQ52867115-89A835FA-BCCE-4956-9614-F1D036D36110Q53176024-829BF733-F20E-40DB-AEC0-3C59BF335735Q57450687-7A2A35CB-2522-40A8-BD1F-0BE7E1CCF3AC
P2860
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase II trial of everolimus a ...... neck squamous cell carcinoma.
@en
type
label
Phase II trial of everolimus a ...... neck squamous cell carcinoma.
@en
prefLabel
Phase II trial of everolimus a ...... neck squamous cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Phase II trial of everolimus a ...... neck squamous cell carcinoma.
@en
P2093
E Massarelli
G R Blumenschein
J R Canales
J V Heymach
L E Ginsberg
P2860
P304
P356
10.1093/ANNONC/MDV194
P577
2015-05-29T00:00:00Z